Do analysts prefer ITRM or RVPH?

Reviva Pharmaceuticals has a consensus price target of $53.33, suggesting a potential upside of 11,011.11%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Iterum Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Reviva Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20

Is ITRM or RVPH more profitable?

Iterum Therapeutics' return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Iterum Therapeutics N/A N/A -65.54% Reviva Pharmaceuticals N/A -391.58% -119.08%

Does the media prefer ITRM or RVPH?

In the previous week, Iterum Therapeutics and Iterum Therapeutics both had 1 articles in the media. Iterum Therapeutics' average media sentiment score of 0.00 equaled Reviva Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iterum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Reviva Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend SNOA or ITRM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Does the media prefer SNOA or ITRM?

In the previous week, Sonoma Pharmaceuticals had 1 more articles in the media than Iterum Therapeutics. MarketBeat recorded 2 mentions for Sonoma Pharmaceuticals and 1 mentions for Iterum Therapeutics. Iterum Therapeutics' average media sentiment score of 0.00 beat Sonoma Pharmaceuticals' score of -0.36 indicating that Iterum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sonoma Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Iterum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ITRM or LEXX?

Lexaria Bioscience has a consensus target price of $22.50, suggesting a potential upside of 573.65%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Lexaria Bioscience is more favorable than Iterum Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ITRM or LEXX more profitable?

Iterum Therapeutics' return on equity of 0.00% beat Lexaria Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Iterum Therapeutics N/A N/A -65.54% Lexaria Bioscience N/A -174.93% -143.89%

Does the media favor ITRM or LEXX?

In the previous week, Iterum Therapeutics and Iterum Therapeutics both had 1 articles in the media. Iterum Therapeutics' average media sentiment score of 0.00 equaled Lexaria Bioscience'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iterum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lexaria Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate NCNA or ITRM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is NCNA or ITRM more profitable?

Iterum Therapeutics' return on equity of 0.00% beat NuCana's return on equity. Company Net Margins Return on Equity Return on Assets NuCana N/A -41.90% -33.69% Iterum Therapeutics N/A N/A -65.54%

Do analysts rate ITRM or PULM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Pulmatrix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ITRM or PULM more profitable?

Iterum Therapeutics' return on equity of 0.00% beat Pulmatrix's return on equity. Company Net Margins Return on Equity Return on Assets Iterum Therapeutics N/A N/A -65.54% Pulmatrix N/A -125.65% -95.19%

Does the media refer more to ITRM or PULM?

In the previous week, Iterum Therapeutics and Iterum Therapeutics both had 1 articles in the media. Iterum Therapeutics' average media sentiment score of 0.00 equaled Pulmatrix'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iterum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pulmatrix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Iterum Therapeutics (ITRM) Competitors

$0.03 0.00 (0.00%)

As of 09/23/2026

Compare

ITRM vs. RVPH, SNOA, LEXX, NCNA, and PULM

Should you buy Iterum Therapeutics stock or one of its competitors? Iterum Therapeutics's main competitors and comparable companies include Reviva Pharmaceuticals (RVPH), Sonoma Pharmaceuticals (SNOA), Lexaria Bioscience (LEXX), NuCana (NCNA), and Pulmatrix (PULM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Iterum Therapeutics compare to Reviva Pharmaceuticals?

Iterum Therapeutics (NASDAQ:ITRM) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 2.0% of Iterum Therapeutics shares are owned by insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Reviva Pharmaceuticals has lower revenue, but higher earnings than Iterum Therapeutics. Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$1.85	N/A

Iterum Therapeutics has a beta of 2.96, meaning that its share price is 196% more volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market.

Iterum Therapeutics' return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%

In the previous week, Iterum Therapeutics and Iterum Therapeutics both had 1 articles in the media. Iterum Therapeutics' average media sentiment score of 0.00 equaled Reviva Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iterum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Reviva Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Reviva Pharmaceuticals has a consensus price target of $53.33, suggesting a potential upside of 11,011.11%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Iterum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Iterum Therapeutics and Reviva Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Iterum Therapeutics compare to Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals (NASDAQ:SNOA) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

In the previous week, Sonoma Pharmaceuticals had 1 more articles in the media than Iterum Therapeutics. MarketBeat recorded 2 mentions for Sonoma Pharmaceuticals and 1 mentions for Iterum Therapeutics. Iterum Therapeutics' average media sentiment score of 0.00 beat Sonoma Pharmaceuticals' score of -0.36 indicating that Iterum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sonoma Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Iterum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Iterum Therapeutics has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -10.33%. Iterum Therapeutics' return on equity of 0.00% beat Sonoma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sonoma Pharmaceuticals	-10.33%	-21.41%	-6.08%
Iterum Therapeutics	N/A	N/A	-65.54%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are held by institutional investors. 1.0% of Sonoma Pharmaceuticals shares are held by insiders. Comparatively, 2.0% of Iterum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Sonoma Pharmaceuticals has higher revenue and earnings than Iterum Therapeutics. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonoma Pharmaceuticals	$19.53M	0.31	-$3.17M	-$1.22	N/A
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A

Sonoma Pharmaceuticals has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market. Comparatively, Iterum Therapeutics has a beta of 2.96, indicating that its stock price is 196% more volatile than the broader market.

Summary

Iterum Therapeutics beats Sonoma Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Iterum Therapeutics compare to Lexaria Bioscience?

Iterum Therapeutics (NASDAQ:ITRM) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

In the previous week, Iterum Therapeutics and Iterum Therapeutics both had 1 articles in the media. Iterum Therapeutics' average media sentiment score of 0.00 equaled Lexaria Bioscience'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iterum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lexaria Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

9.2% of Iterum Therapeutics shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 2.0% of Iterum Therapeutics shares are held by insiders. Comparatively, 8.4% of Lexaria Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Iterum Therapeutics has a beta of 2.96, meaning that its share price is 196% more volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market.

Iterum Therapeutics' return on equity of 0.00% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Lexaria Bioscience	N/A	-174.93%	-143.89%

Lexaria Bioscience has a consensus target price of $22.50, suggesting a potential upside of 573.65%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Lexaria Bioscience is more favorable than Iterum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lexaria Bioscience has lower revenue, but higher earnings than Iterum Therapeutics. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A
Lexaria Bioscience	$194K	28.46	-$11.90M	-$5.10	N/A

Summary

Lexaria Bioscience beats Iterum Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Iterum Therapeutics compare to NuCana?

NuCana (NASDAQ:NCNA) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

Iterum Therapeutics' return on equity of 0.00% beat NuCana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-41.90%	-33.69%
Iterum Therapeutics	N/A	N/A	-65.54%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Iterum Therapeutics has higher revenue and earnings than NuCana. NuCana is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71M	-$3.81	N/A
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A

44.0% of NuCana shares are owned by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are owned by institutional investors. 31.2% of NuCana shares are owned by insiders. Comparatively, 2.0% of Iterum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

NuCana has a beta of 2.23, meaning that its share price is 123% more volatile than the broader market. Comparatively, Iterum Therapeutics has a beta of 2.96, meaning that its share price is 196% more volatile than the broader market.

In the previous week, Iterum Therapeutics had 1 more articles in the media than NuCana. MarketBeat recorded 1 mentions for Iterum Therapeutics and 0 mentions for NuCana. NuCana's average media sentiment score of 0.00 equaled Iterum Therapeutics'average media sentiment score.

Company	Overall Sentiment
NuCana	Neutral
Iterum Therapeutics	Neutral

Summary

Iterum Therapeutics beats NuCana on 8 of the 11 factors compared between the two stocks.

How does Iterum Therapeutics compare to Pulmatrix?

Iterum Therapeutics (NASDAQ:ITRM) and Pulmatrix (NASDAQ:PULM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 11.8% of Pulmatrix shares are owned by institutional investors. 2.0% of Iterum Therapeutics shares are owned by company insiders. Comparatively, 0.6% of Pulmatrix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Iterum Therapeutics' return on equity of 0.00% beat Pulmatrix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Pulmatrix	N/A	-125.65%	-95.19%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Pulmatrix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Iterum Therapeutics has a beta of 2.96, suggesting that its share price is 196% more volatile than the broader market. Comparatively, Pulmatrix has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market.

In the previous week, Iterum Therapeutics and Iterum Therapeutics both had 1 articles in the media. Iterum Therapeutics' average media sentiment score of 0.00 equaled Pulmatrix'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iterum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pulmatrix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pulmatrix has higher revenue and earnings than Iterum Therapeutics. Pulmatrix is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390K	4.10	-$24.77M	-$0.75	N/A
Pulmatrix	$7.81M	0.79	-$5.16M	-$1.10	N/A

Summary

Iterum Therapeutics beats Pulmatrix on 8 of the 11 factors compared between the two stocks.

Get Iterum Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ITRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ITRM vs. The Competition

Export

Metric	Iterum Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.60M	$12.62B	$7.28B	$13.01B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	-0.04	797.33	274.92	25.63
Price / Sales	4.10	852.31	673.28	90.00
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	-0.20	10.60	10.34	6.27
Net Income	-$24.77M	$2.84B	$3.49B	$360.12M
7 Day Performance	N/A	-0.78%	-1.13%	-0.31%
1 Month Performance	N/A	-1.63%	-3.55%	-3.67%
1 Year Performance	N/A	2.51%	14.81%	5.14%

Iterum Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ITRM Iterum Therapeutics	0.021 of 5 stars	$0.03 flat	N/A	N/A	$1.60M	$390K	N/A	10	News Coverage
RVPH Reviva Pharmaceuticals	1.5918 of 5 stars	$0.48 flat	$53.33 +11,011.1%	-91.6%	$6.29M	N/A	N/A	5	Gap Up
SNOA Sonoma Pharmaceuticals	0.594 of 5 stars	$1.28 -0.8%	N/A	-69.1%	$6.18M	$19.53M	N/A	180	News Coverage Positive News
LEXX Lexaria Bioscience	1.4745 of 5 stars	$3.21 -9.6%	$22.50 +600.9%	-83.6%	$5.87M	$710K	N/A	7
NCNA NuCana	0.3215 of 5 stars	$1.30 -1.5%	N/A	-66.3%	$5.49M	N/A	N/A	30	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ITRM) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Iterum Therapeutics (ITRM) Competitors

ITRM vs. RVPH, SNOA, LEXX, NCNA, and PULM

How does Iterum Therapeutics compare to Reviva Pharmaceuticals?

Summary

How does Iterum Therapeutics compare to Sonoma Pharmaceuticals?

Summary

How does Iterum Therapeutics compare to Lexaria Bioscience?

Summary

How does Iterum Therapeutics compare to NuCana?

Summary

How does Iterum Therapeutics compare to Pulmatrix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ITRM vs. The Competition

Iterum Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Iterum Therapeutics (ITRM) Competitors

ITRM vs. RVPH, SNOA, LEXX, NCNA, and PULM

How does Iterum Therapeutics compare to Reviva Pharmaceuticals?

Do insiders and institutionals hold more shares of ITRM or RVPH?

Which has preferable earnings and valuation, ITRM or RVPH?

Which has more volatility and risk, ITRM or RVPH?

Is ITRM or RVPH more profitable?

Does the media prefer ITRM or RVPH?

Do analysts prefer ITRM or RVPH?

Summary

How does Iterum Therapeutics compare to Sonoma Pharmaceuticals?

Does the media prefer SNOA or ITRM?

Is SNOA or ITRM more profitable?

Do analysts recommend SNOA or ITRM?

Do institutionals & insiders have more ownership in SNOA or ITRM?

Which has stronger earnings & valuation, SNOA or ITRM?

Which has more risk & volatility, SNOA or ITRM?

Summary

How does Iterum Therapeutics compare to Lexaria Bioscience?

Does the media favor ITRM or LEXX?

Do insiders & institutionals have more ownership in ITRM or LEXX?

Which has more risk and volatility, ITRM or LEXX?

Is ITRM or LEXX more profitable?

Do analysts recommend ITRM or LEXX?

Which has higher earnings and valuation, ITRM or LEXX?

Summary

How does Iterum Therapeutics compare to NuCana?

Is NCNA or ITRM more profitable?

Do analysts rate NCNA or ITRM?

Which has stronger earnings and valuation, NCNA or ITRM?

Do institutionals & insiders hold more shares of NCNA or ITRM?

Which has more volatility and risk, NCNA or ITRM?

Does the media prefer NCNA or ITRM?

Summary

How does Iterum Therapeutics compare to Pulmatrix?

Do insiders and institutionals believe in ITRM or PULM?

Is ITRM or PULM more profitable?

Do analysts rate ITRM or PULM?

Which has more volatility & risk, ITRM or PULM?

Does the media refer more to ITRM or PULM?

Which has stronger valuation & earnings, ITRM or PULM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ITRM vs. The Competition

Iterum Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools